We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Read MoreHide Full Article
Key Takeaways
ALLO's Q2 loss of 23 cents beats estimates. No sales were reported due to the absence of marketed products.
R&D and G&A costs fell. Cash burn in 2025 is projected to be $150M, extending the runway into late 2027.
CAR T pipeline advances include pivotal ALPHA3 study and new autoimmune-focused RESOLUTION trial.
Allogene Therapeutics (ALLO - Free Report) incurred a second-quarter 2025 loss of 23 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 28 cents. In the year-ago period, the company had incurred a loss of 35 cents per share.
The company currently lacks a marketed product in its portfolio. As a result, it did not report any sales during the second quarter.
ALLO's Q2 Earnings in Detail
Research & development (R&D) expenses totaled $40.2 million, down 20.2% from the year-ago quarter’s level.
General and administrative (G&A) expenses declined 11.2% year over year to $14.3 million.
As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents and investments compared with $335.5 million as of March 31, 2025.
Year to date, shares of Allogene have plunged 51.2% against the industry’s rise of 0.5%.
Image Source: Zacks Investment Research
ALLO's 2025 Guidance
The company continues to expect operating expenses in 2025 to be around $230 million.
Cash burn for 2025 is expected to be around $150 million. Based on these expected savings, Allogene claims that its cash runway will fund operations into the second half of 2027.
Earlier this year, Allogene implemented strategic cost realignment initiatives aimed at optimizing operations and extending its financial runway.
ALLO's Recent Pipeline Updates
Allogene is developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs.
The pivotal phase II ALPHA3 study is evaluating its lead drug cema-cel as a potential first-line treatment for newly diagnosed and treated large B cell lymphoma (LBCL) patients who are likely to relapse and need further therapy. The futility analysis from this study is expected in the first half of 2026.
Earlier this month, the company announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen in the ALPHA3 study evaluating cema-cel in first-line consolidation for LBCL.
The ALPHA3 study is now being conducted with two arms, comparing cema-cel after standard FC lymphodepletion to observation – the current standard of care.
Allogene is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases. During the second quarter, the company initiated the phase I RESOLUTION basket study in rheumatology, evaluating a new candidate, ALLO-329, across various autoimmune diseases, including systemic lupus erythematosus, idiopathic inflammatory myopathies and systemic sclerosis. The company expects the first update from this study in the first half of 2026, which will include both biomarker and clinical proof-of-concept data.
ALLO-316, the company’s first CAR T candidate for solid tumors, is being evaluated in the phase I TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression.
The company has reached alignment with the FDA on the pivotal study design for ALLO-316, creating a pathway for potential partnership discussions to advance the program.
Allogene Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.90. Loss per share estimates for 2026 have narrowed from $4.27 to $4.21 during the same period. AKRO stock has surged 73.6% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Amarin’s 2025 loss per share have narrowed from $2.30 to $2.25. Loss per share estimates for 2026 have narrowed from $1.78 to $1.61 during the same period. AMRN stock has rallied 54.6% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 22.97%.
In the past 60 days, estimates for Aligos Therapeutics’ 2025 loss per share have narrowed from $9.71 to $8.26. Loss per share estimates for 2026 have narrowed from $10.45 to $8.78 during the same period. ALGS stock has plunged 80.8% year to date.
Aligos Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 15.45%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Key Takeaways
Allogene Therapeutics (ALLO - Free Report) incurred a second-quarter 2025 loss of 23 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 28 cents. In the year-ago period, the company had incurred a loss of 35 cents per share.
The company currently lacks a marketed product in its portfolio. As a result, it did not report any sales during the second quarter.
ALLO's Q2 Earnings in Detail
Research & development (R&D) expenses totaled $40.2 million, down 20.2% from the year-ago quarter’s level.
General and administrative (G&A) expenses declined 11.2% year over year to $14.3 million.
As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents and investments compared with $335.5 million as of March 31, 2025.
Year to date, shares of Allogene have plunged 51.2% against the industry’s rise of 0.5%.
Image Source: Zacks Investment Research
ALLO's 2025 Guidance
The company continues to expect operating expenses in 2025 to be around $230 million.
Cash burn for 2025 is expected to be around $150 million. Based on these expected savings, Allogene claims that its cash runway will fund operations into the second half of 2027.
Earlier this year, Allogene implemented strategic cost realignment initiatives aimed at optimizing operations and extending its financial runway.
ALLO's Recent Pipeline Updates
Allogene is developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs.
The pivotal phase II ALPHA3 study is evaluating its lead drug cema-cel as a potential first-line treatment for newly diagnosed and treated large B cell lymphoma (LBCL) patients who are likely to relapse and need further therapy. The futility analysis from this study is expected in the first half of 2026.
Earlier this month, the company announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen in the ALPHA3 study evaluating cema-cel in first-line consolidation for LBCL.
The ALPHA3 study is now being conducted with two arms, comparing cema-cel after standard FC lymphodepletion to observation – the current standard of care.
Allogene is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases. During the second quarter, the company initiated the phase I RESOLUTION basket study in rheumatology, evaluating a new candidate, ALLO-329, across various autoimmune diseases, including systemic lupus erythematosus, idiopathic inflammatory myopathies and systemic sclerosis. The company expects the first update from this study in the first half of 2026, which will include both biomarker and clinical proof-of-concept data.
ALLO-316, the company’s first CAR T candidate for solid tumors, is being evaluated in the phase I TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression.
The company has reached alignment with the FDA on the pivotal study design for ALLO-316, creating a pathway for potential partnership discussions to advance the program.
Allogene Therapeutics, Inc. Price, Consensus and EPS Surprise
Allogene Therapeutics, Inc. price-consensus-eps-surprise-chart | Allogene Therapeutics, Inc. Quote
ALLO's Zacks Rank & Stocks to Consider
Allogene currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) , Amarin (AMRN - Free Report) and Aligos Therapeutics (ALGS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.90. Loss per share estimates for 2026 have narrowed from $4.27 to $4.21 during the same period. AKRO stock has surged 73.6% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Amarin’s 2025 loss per share have narrowed from $2.30 to $2.25. Loss per share estimates for 2026 have narrowed from $1.78 to $1.61 during the same period. AMRN stock has rallied 54.6% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 22.97%.
In the past 60 days, estimates for Aligos Therapeutics’ 2025 loss per share have narrowed from $9.71 to $8.26. Loss per share estimates for 2026 have narrowed from $10.45 to $8.78 during the same period. ALGS stock has plunged 80.8% year to date.
Aligos Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 15.45%.